Previous 10 | Next 10 |
HOOKIPA Pharma press release ( NASDAQ: HOOK ): Q3 GAAP EPS of -$0.25 beats by $0.02 . Revenue of $2.23M (-42.4% Y/Y) misses by $0.68M . For further details see: HOOKIPA Pharma GAAP EPS of -$0.25 beats by $0.02, revenue of $2.23M misses by $0.68M
Major oncology collaboration and license agreement secured with Roche to develop HB-700 for KRAS-mutated cancers and an additional undisclosed oncology candidate Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer a...
NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced it will release its third quarter 2022 financial res...
NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the Sidoti M...
3 Tips for Finding Popular Penny Stocks to Buy Investing in penny stocks can be a great way to make money, but it can also be very risky. There are a few things you need to know before you start investing in penny stocks . First, you need to understand exactly what is going on in th...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arhendrix / Shutterstock Indonesia Energy (NYSEMKT: INDO ) stock is climbing higher on Thursday after the company announced the discovery of oil in one of its new wells . The big news here is the oil ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Hookipa (NASDAQ: HOOK ) stock is rocketing higher on Thursday after reaching a strategic collaboration and license agreement with Roche (OTCMKTS: RHHBF ). That agreement has the tw...
Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) signed a license agreement with Hookipa Pharma ( NASDAQ: HOOK ) to develop immunotherapy HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. Under the agreement, Hookipa...
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapy HOOKIPA to receive $25 million in upfront cash as well as potential future success-based milestone payments up to approximately $930 million for b...
The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with this event. For further details see: HOOKIPA Pharma (HOOK) August-2022-Investor-Presentation
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com